Letter: levofloxacin resistance – a challenge for treatment of Helicobacter pylori infection. Authors' reply

2012; 67: 170–3. 5. Wang L-H, Cheng H, Hu F-L, Li J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 2010; 16: 2272–7. 6. O’Connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci 2013; 182: 693–5. 7. Seck A, Burucoa C, Dia D, et al. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. Ann Clin Microbiol Antimicrob 2013; 12: 3. 8. Karczewska E, Klesiewicz K, Wojtas-Bonior I, et al. Levofloxacin resistance of Helicobacter pylori strains isolated from patients in southern Poland, between 2006-2012. Acta Pol Pharm 2014; 71: 477–83. 9. Phan TN, Santona A, Tran VH, et al. High rate of levofloxacin resistance in a background of clarithromycin-and metronidazoleresistant Helicobacter pylori in Vietnam. Int J Antimicrob Agents 2015; 45: 244–8. 10. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013; 18: 206–14.

[1]  M. Zamani,et al.  Letter: levofloxacin resistance – a challenge for the treatment of Helicobacter pylori infection , 2017, Alimentary pharmacology & therapeutics.

[2]  E. El-Omar,et al.  Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial , 2016, The Lancet.

[3]  C. Chou,et al.  Systematic review with meta‐analysis: the efficacy of levofloxacin triple therapy as the first‐ or second‐line treatments of Helicobacter pylori infection , 2016, Alimentary pharmacology & therapeutics.

[4]  S. Rubino,et al.  High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam. , 2015, International journal of antimicrobial agents.

[5]  M. Zwolinska-Wcislo,et al.  Levofloxacin resistance of Helicobacter pylori strains isolated from patients in southern Poland, between 2006-2012. , 2014, Acta poloniae pharmaceutica.

[6]  Jung Mogg Kim,et al.  Prevalence of Primary and Secondary Antimicrobial Resistance of Helicobacter pylori in Korea from 2003 through 2012 , 2013, Helicobacter.

[7]  Hsiu‐Po Wang,et al.  Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial , 2013, The Lancet.

[8]  A. Seck,et al.  Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients , 2013, Annals of Clinical Microbiology and Antimicrobials.

[9]  Jiang-Dong Li,et al.  Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. , 2010, World journal of gastroenterology.

[10]  J. Gisbert,et al.  Clinical trial: clarithromycin vs. levofloxacin in first‐line triple and sequential regimens for Helicobacter pylori eradication , 2010, Alimentary pharmacology & therapeutics.

[11]  J. Gisbert,et al.  Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta‐analysis , 2002, Alimentary pharmacology & therapeutics.